PolyPid (NASDAQ:PYPD – Get Free Report) announced its quarterly earnings results on Wednesday. The company reported ($0.35) earnings per share for the quarter, beating the consensus estimate of ($0.47) by $0.12, FiscalAI reports.
Here are the key takeaways from PolyPid’s conference call:
- PolyPid said its rolling NDA submission for D-PLEX100 is underway, with the remaining clinical module expected to be filed imminently, and that the product could qualify for priority review if the FDA accepts the submission.
- Management said U.S. strategic partnership discussions are in late stages, with the goal of supporting a commercial launch in Q1 2027 and prioritizing a partner with strong hospital sales capabilities.
- The company highlighted encouraging data from SHIELD II, including a 64% relative risk reduction in severe wound events, which it believes strengthens the product’s health-economic case for hospitals and payers.
- PolyPid said it is advancing its European MAA strategy and plans to submit the application to the EMA in the third quarter of 2026, subject to upcoming rapporteur meetings.
- Financially, the company reported a Q1 net loss of $7.7 million, cash and short-term deposits of $10.9 million at quarter-end, and said it fully repaid its remaining loan facility after quarter end, leaving it debt-free and funded into the second half of 2026.
PolyPid Stock Down 7.5%
NASDAQ PYPD traded down $0.34 on Wednesday, reaching $4.22. The stock had a trading volume of 127,984 shares, compared to its average volume of 58,029. The stock has a fifty day moving average price of $4.39 and a two-hundred day moving average price of $4.23. PolyPid has a 12-month low of $2.44 and a 12-month high of $5.12. The firm has a market capitalization of $80.52 million, a price-to-earnings ratio of -1.87 and a beta of 1.41.
Institutional Investors Weigh In On PolyPid
Wall Street Analysts Forecast Growth
Several research analysts have recently weighed in on the stock. Wall Street Zen raised shares of PolyPid from a “sell” rating to a “hold” rating in a research report on Saturday, March 14th. Weiss Ratings cut shares of PolyPid from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, May 1st. Finally, HC Wainwright reissued a “buy” rating and set a $13.00 price target on shares of PolyPid in a research report on Wednesday, February 11th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $12.25.
Get Our Latest Analysis on PolyPid
PolyPid Company Profile
PolyPid Ltd is a clinical‐stage biotechnology company focused on polymer‐based drug delivery technologies designed to enhance the performance of therapeutic agents at mucosal surfaces. Leveraging its proprietary Mucoadhesive & Mucus‐Penetrating (MMP) platform, PolyPid develops long‐acting formulations for ocular, oral and pulmonary indications. Its lead candidates include OncoTears and OralTear, therapies targeting dry eye and dry mouth conditions, respectively, as well as Paclical, a polymer‐formulated paclitaxel designed to improve tolerability and antitumor activity in oncology patients.
Founded in 2003 and headquartered in Jerusalem, Israel, PolyPid has assembled an international patent portfolio covering key markets in North America, Europe and Asia.
Read More
- Five stocks we like better than PolyPid
- D-Wave Earnings Looked Weak, But Investors May Be Missing This
- Nebius Upside Expands as AI Feedback Loop Intensifies
- Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell
- Plug Power Flips The Switch On Profitability
Receive News & Ratings for PolyPid Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PolyPid and related companies with MarketBeat.com's FREE daily email newsletter.
